Cara Therapeutics(CARA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CARA Cara Therapeutics

Market Closed 06-14 16:00:00 EDT

0.3500

-0.0936

-21.10%

盘后0.3501

+0.0001+0.03%

19:57 EDT

High0.4569	Low0.3400	Vol2.14M
Open0.4500	D1 Closing0.4436	Amplitude26.35%
Mkt Cap19.14M	Tradable Cap16.31M	Total Shares54.68M
T/O889.06K	T/O Rate4.59%	Tradable Shares46.61M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"CARA","market":"US","secType":"STK","nameCN":"Cara Therapeutics","latestPrice":0.35,"timestamp":1718395200000,"preClose":0.4436,"halted":0,"volume":2141418,"hourTrading":{"tag":"盘后","latestPrice":0.3501,"preClose":0.35,"latestTime":"19:57 EDT","volume":72380,"amount":25240.4189,"timestamp":1718409474041},"delay":0,"floatShares":46606116,"shares":54675954,"eps":-2.259577,"marketStatus":"Market Closed","change":-0.0936,"latestTime":"06-14 16:00:00 EDT","open":0.45,"high":0.4569,"low":0.34,"amount":889059.577739,"amplitude":0.263526,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-2.259577,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1718611200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1391144400000,"exchange":"NASDAQ","adjPreClose":0.4436,"preHourTrading":{"tag":"盘前","latestPrice":0.445,"preClose":0.4436,"latestTime":"09:19 EDT","volume":2047,"amount":938.040902,"timestamp":1718371159965},"postHourTrading":{"tag":"盘后","latestPrice":0.3501,"preClose":0.35,"latestTime":"19:57 EDT","volume":72380,"amount":25240.4189,"timestamp":1718409474041},"volumeRatio":2.3997802626893674,"impliedVol":1.6901,"impliedVolPercentile":0.4008},"requestUrl":"/m/hq/s/CARA","defaultTab":"news","newsList":[{"id":"2443819296","title":"Chipotle, McDonald's initiated: Wall Street's top analyst calls","url":"https://stock-news.laohu8.com/highlight/detail?id=2443819296","media":"The Fly","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2443819296?lang=en_us&edition=fundamental","pubTime":"2024-06-13 21:51","pubTimestamp":1718286683,"startTime":"0","endTime":"0","summary":"The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly.Top 5 Upgrades:. Wolfe Research upgraded 3M  to Outperform from Peer Perform with a $125 price target. The company's new CEO Bill Brown \"brings The Right Stuff to 3M,\" providing more confidence in the medium-term earnings outlook, the firm tells investors in a research note.Barclays downgraded NextEra Energy Partners  to Underweight from Equal Weight with a price target of $25, down from $32. With limited debt capacity should the company want to stay within its credit ratings, and an \"extremely high\" payout ratio of 95%, NextEra has limited potential options outside a distribution cut, with a reduction of at least 45% necessary, to pay off its remaining convertible equity portfolio financings, the firm tells investors in a research note.Janney Montgomery Scott downgraded Generac  to Neutral from Buy with a fa","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/zUit8GQVW5kcaTZHEPMI9Q--~B/aD02Mjg7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/the_fly_169/5039a5ccc6ec98e1b92bc672330bfcec","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/zUit8GQVW5kcaTZHEPMI9Q--~B/aD02Mjg7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/the_fly_169/5039a5ccc6ec98e1b92bc672330bfcec"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/chipotle-mcdonalds-initiated-wall-streets-135123436.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4127","ROP","KMB","LU0320765059.SGD","LU1880383366.USD","CARA","BK4532","DPZ","NEP","LU1267930730.SGD","GEV","SG","SGXZ99366536.SGD","LU0880133367.SGD","LU1430594728.SGD","PAR","SGXZ81514606.USD","IE00BMG7P587.USD","BK4107","MMM","CMG","GNRC","MAA","WEN","IE00BFSS7M15.SGD","LU1244550494.USD","BK4548","LU1718418525.SGD","JACK","IE00BSNM7G36.USD","BK4227","BK4531","BK4534","NTES","YUM","LU1807302812.USD","LU1861220207.SGD","WING","PAGS","BK4106","SBUX","LU2065169927.USD","LU1861217088.USD","LU2065171402.SGD","LU2133065610.SGD","MCD","LU0417517546.SGD","QSR","BK4547","WRB"],"gpt_icon":0},{"id":"2443689583","title":"Dow Tumbles Over 100 Points; US Producer Prices Decline In May","url":"https://stock-news.laohu8.com/highlight/detail?id=2443689583","media":"Benzinga","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2443689583?lang=en_us&edition=fundamental","pubTime":"2024-06-13 21:45","pubTimestamp":1718286342,"startTime":"0","endTime":"0","summary":" ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/06/39312852/dow-tumbles-over-100-points-us-producer-prices-decline-in-may","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4161",".IXIC","BK4192","SQQQ","BK4007","BURU","QQQ","PSQ","BK4122","STSS","BK4139","QLD","CARA","IONM","BK4583","NQmain","QID","TQQQ","EJH","BK4196","BK4198","PCOM","BRTX","MNQmain"],"gpt_icon":0},{"id":"2443506718","title":"BUZZ-Cara drops on scrapping of neurological condition study, strategic options plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2443506718","media":"Reuters","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2443506718?lang=en_us&edition=fundamental","pubTime":"2024-06-13 18:57","pubTimestamp":1718276270,"startTime":"0","endTime":"0","summary":"** Shares of Cara Therapeutics    fall 20.03% to 54 cents premarket   ** Co late on Wednesday said it will wind down studying its drug for a type of neurological condition after it did not show a meaningful clinical benefit at any dose compared to placebo   ** Adds, will explore strategic alternatives   ** Co was studying oral difelikefalin in adult patients with notalgia paresthetica, a neurological condition that causes intense itching, in a mid-to-late stage trial    ** Brokerage Canaccord Genuity downgrades to hold from buy, cuts PT to $1 from $10   ** Says it is difficult to predict what the results of any upcoming strategic initiatives might be   ** Up to last close, stock down ~9% YTD ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CARA","BUZZ"],"gpt_icon":0},{"id":"2443150547","title":"Needham Downgrades Cara Therapeutics to Hold From Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2443150547","media":"MT Newswires Live","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2443150547?lang=en_us&edition=fundamental","pubTime":"2024-06-13 18:38","pubTimestamp":1718275135,"startTime":"0","endTime":"0","summary":"(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CARA"],"gpt_icon":0},{"id":"2443466505","title":"Cara Therapeutics Cut to Neutral From Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2443466505","media":"Dow Jones","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2443466505?lang=en_us&edition=fundamental","pubTime":"2024-06-13 18:33","pubTimestamp":1718274780,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CARA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 13, 2024 06:33 ET (10:33 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CARA"],"gpt_icon":0},{"id":"2443055615","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Cara Therapeutics (CARA), Affimed (AFMD) and Ventyx Biosciences (VTYX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2443055615","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2443055615?lang=en_us&edition=fundamental","pubTime":"2024-06-13 18:22","pubTimestamp":1718274159,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cara Therapeutics (CARA – Research Report), Affimed (AFMD – Resea...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-cara-therapeutics-cara-affimed-afmd-and-ventyx-biosciences-vtyx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-cara-therapeutics-cara-affimed-afmd-and-ventyx-biosciences-vtyx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","VTYX","AFMD","BK4137","CARA","BK4139","HCSG"],"gpt_icon":0},{"id":"2443503239","title":"Cara Therapeutics Cut to Hold From Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2443503239","media":"Dow Jones","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2443503239?lang=en_us&edition=fundamental","pubTime":"2024-06-13 18:18","pubTimestamp":1718273880,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CARA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 13, 2024 06:18 ET (10:18 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CARA"],"gpt_icon":0},{"id":"2443550556","title":"H.C. Wainwright downgrades Cara Therapeutics (CARA) to a Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2443550556","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2443550556?lang=en_us&edition=fundamental","pubTime":"2024-06-13 18:17","pubTimestamp":1718273857,"startTime":"0","endTime":"0","summary":"Cara Therapeutics (CARA – Research Report) received a Hold rating and price target from H.C. Wainwright analyst Oren Livnat today. The company’s sh...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-downgrades-cara-therapeutics-cara-to-a-hold?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-downgrades-cara-therapeutics-cara-to-a-hold?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CARA"],"gpt_icon":0},{"id":"2443625570","title":"Canaccord Genuity Downgrades Cara Therapeutics to Hold From Buy, Adjusts Price Target to $1 From $10","url":"https://stock-news.laohu8.com/highlight/detail?id=2443625570","media":"MT Newswires Live","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2443625570?lang=en_us&edition=fundamental","pubTime":"2024-06-13 17:46","pubTimestamp":1718271974,"startTime":"0","endTime":"0","summary":"Price: 0.5901, Change: -0.09, Percent Change: -13.16","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CARA"],"gpt_icon":0},{"id":"2443783135","title":"U.S. RESEARCH ROUNDUP-Avidity Biosciences, Broadcom, Cara Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2443783135","media":"Reuters","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2443783135?lang=en_us&edition=fundamental","pubTime":"2024-06-13 15:24","pubTimestamp":1718263485,"startTime":"0","endTime":"0","summary":"June 13 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Avidity Biosciences, Broadcom and Cara Therapeutics, on Thursday","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0198837287.USD","MTH","LU0957808578.USD","LU0170899867.USD","ENOV","LU0097036916.USD","AVGO","LU1642822529.SGD","LU0689472784.USD","LU1670711040.USD","LU0466842654.USD","RNA","CASY","LU0070302665.USD","LU1242518931.SGD","BK4082","CARA","LU0861579265.USD","CELH","LU1670710588.SGD","LU1244550494.USD","LU2065732104.USD","LXEO","WMB","LU0820561909.HKD","LU0444971666.USD","LU1720051108.HKD","LU0820561818.USD","GLW","LU1992135399.USD","BK4088","SG9999018865.SGD","IE00BD6J9T35.USD","LU1670711123.USD","LU1670627923.USD","LU0320765489.SGD","SG9999014898.SGD","IE00BMPRXN33.USD","LU1242518857.USD","LU0056508442.USD","IE00B19Z6F94.USD","AVGOP","LU1670628061.USD","CRL","LU2065731478.USD","LU1670710661.SGD","APH","BK4533","TWST","LU0390134368.USD"],"gpt_icon":0},{"id":"2443351341","title":"Cara Therapeutics Halts Trials for Itch Medication Difelikefalin","url":"https://stock-news.laohu8.com/highlight/detail?id=2443351341","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2443351341?lang=en_us&edition=fundamental","pubTime":"2024-06-13 06:00","pubTimestamp":1718229602,"startTime":"0","endTime":"0","summary":"Cara Therapeutics (CARA) has provided an update. Cara Therapeutics, Inc. recently announced that their oral medication difelikefalin did not show s...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cara-therapeutics-halts-trials-for-itch-medication-difelikefalin?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cara-therapeutics-halts-trials-for-itch-medication-difelikefalin?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CARA"],"gpt_icon":0},{"id":"2443594452","title":"Cara Therapeutics to Discontinue Clinical Program to Treat Notalgia Paresthetica Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2443594452","media":"Dow Jones","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2443594452?lang=en_us&edition=fundamental","pubTime":"2024-06-13 04:24","pubTimestamp":1718223840,"startTime":"0","endTime":"0","summary":"Cara Therapeutics said it is discounting a clinical program to treat patients with notalgia paresthetica on the outcome from the dose-finding part A of its Kourage-1 study.The commercial-stage biopharmaceutical company on Wednesday said it is  disappointed that oral difelikefalin failed to demonstrate a meaningful clinical benefit at any dose compared to placebo during the study.Notalgia paresthetica is a chronic condition that causes a localized itch in the upper back.\"We will be winding down the Phase 2/3 clinical program in notalgia paresthetica and exploring strategic alternatives focused on maximizing shareholder value,\" Chief Executive Christopher Posner said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CARA"],"gpt_icon":0},{"id":"2443944395","title":"Cara Therapeutics Discontinues NP Program After Drug Study Fails to Show Clinical Benefit -- Shares Drop","url":"https://stock-news.laohu8.com/highlight/detail?id=2443944395","media":"MT Newswires Live","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2443944395?lang=en_us&edition=fundamental","pubTime":"2024-06-13 04:23","pubTimestamp":1718223800,"startTime":"0","endTime":"0","summary":"Cara Therapeutics  said late Wednesday the results of a trial assessing the efficacy and safety of oral difelikefalin to treat notalgia paresthetica, a nerve disorder, didn't demonstrate meaningful clinical benefit compared to placebo.The company has decided to discontinue its clinical program in notalgia paresthetica.\"We will be winding down the Phase 2/3 clinical program in [notalgia paresthetica] and exploring strategic alternatives focused on maximizing shareholder value,\" said Cara Chief Executive Christopher Posner.The company said, as of March 31, it had about $70 million in cash, cash equivalents, and marketable securities.Cara shares were down more than 15% in after-hours activity.Price: 0.5761, Change: -0.10, Percent Change: -15.22","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","CARA"],"gpt_icon":0},{"id":"2443597849","title":"Cara to seek strategic alternatives after difelikefalin trial failure in pruritus","url":"https://stock-news.laohu8.com/highlight/detail?id=2443597849","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2443597849?lang=en_us&edition=fundamental","pubTime":"2024-06-13 04:19","pubTimestamp":1718223571,"startTime":"0","endTime":"0","summary":"Cara Therapeutics  said that it will seek strategic alternatives after its pruritus candidate, difelikefalin, failed in a key trial. Difelikefalin did not demonstrate a meaningful clinical benefit at any dose versus placebo in the KOURAGE-1 Part A trial. As a result, the company will wind down the phase 2/3 program. The drug was under investigation for prurirus, also known as itching, associated with notalgia paresthetica.  As of March 31, Cara had $70M in cash, cash equivalents, and marketable securities.","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1196157315/image_1196157315.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1196157315/image_1196157315.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4115351-cara-seek-strategic-alternatives-difelikefalin-trial-failure-pruritus","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["CARA","BK4007"],"gpt_icon":0},{"id":"2443659467","title":"Cara Therapeutics discontinues study on a neurological condition as drug fails","url":"https://stock-news.laohu8.com/highlight/detail?id=2443659467","media":"Reuters","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2443659467?lang=en_us&edition=fundamental","pubTime":"2024-06-13 04:16","pubTimestamp":1718223396,"startTime":"0","endTime":"0","summary":"June 12  - Cara Therapeutics    said on Wednesday it will discontinue a mid-to-late stage study for a neurological condition that causes itching after its experimental drug did not demonstrate a meaningful clinical benefit compared to placebo. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CARA","BK4007"],"gpt_icon":0},{"id":"2443461591","title":"Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica","url":"https://stock-news.laohu8.com/highlight/detail?id=2443461591","media":"GlobeNewswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2443461591?lang=en_us&edition=fundamental","pubTime":"2024-06-13 04:01","pubTimestamp":1718222460,"startTime":"0","endTime":"0","summary":"– Oral difelikefalin did not demonstrate meaningful clinical benefit compared to placebo – – Company will discontinue clinical program in NP and explore strategic alternatives – STAMFORD, Conn., June ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/06/12/2897873/29236/en/Cara-Therapeutics-Announces-Outcome-of-Part-A-of-KOURAGE-1-Study-Evaluating-Oral-Difelikefalin-in-Notalgia-Paresthetica.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CARA","BK4007"],"gpt_icon":0},{"id":"2439603709","title":"Nektar, Verastem among healthcare additions in Russell Microcap; Assertio, Sangamo removed","url":"https://stock-news.laohu8.com/highlight/detail?id=2439603709","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2439603709?lang=en_us&edition=fundamental","pubTime":"2024-05-31 04:55","pubTimestamp":1717102501,"startTime":"0","endTime":"0","summary":"In its annual 2024 Russell index reconstitution, about 213 companies will be added and 198 deleted from the Russell Microcap Index.The following notable healthcare companies will be added and deleted from the Russell Microcap Index:. Notable additions: Inovio Pharmaceuticals , Ocugen , Nektar Therapeutics , Verastem .Notable deletions: Assertio , Sangamo Therapeutics , Cara Therapeutics , Butterfly Network , Therapeutic SMD ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4111764-nektar-verastem-among-healthcare-additions-in-russell-microcap-assertio-sangamo-removed","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4007","BK4563","CARA","ASRT","BK4556","SGMO","BK4139","NKTR","BK4583","BK4568","OCGN","VSTM","TXMD","BFLY","INO","BK4082"],"gpt_icon":0},{"id":"2437786731","title":"Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS) and Cara Therapeutics (CARA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2437786731","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2437786731?lang=en_us&edition=fundamental","pubTime":"2024-05-23 18:41","pubTimestamp":1716460864,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Apellis Pharmaceuticals (APLS – Research Report) and Cara Therape...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-apellis-pharmaceuticals-apls-and-cara-therapeutics-cara?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-apellis-pharmaceuticals-apls-and-cara-therapeutics-cara?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","BK4139","CARA","BK4007","HCSG","APLS","BK4588","BK4137","BK4585","LU1093756325.SGD","LU1093756168.USD"],"gpt_icon":0},{"id":"2437731319","title":"Cara Therapeutics Price Target Maintained With a $5.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2437731319","media":"Dow Jones","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2437731319?lang=en_us&edition=fundamental","pubTime":"2024-05-23 18:37","pubTimestamp":1716460620,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CARA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 23, 2024 06:37 ET (10:37 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CARA","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.caratherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.4393},{"period":"1month","weight":-0.5394},{"period":"3month","weight":-0.6014},{"period":"6month","weight":-0.7154},{"period":"1year","weight":-0.8916},{"period":"ytd","weight":-0.5289}],"compareEarnings":[{"period":"1week","weight":0.0164},{"period":"1month","weight":0.0245},{"period":"3month","weight":0.0646},{"period":"6month","weight":0.1565},{"period":"1year","weight":0.2263},{"period":"ytd","weight":0.1419}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.067158},{"month":2,"riseRate":0.363636,"avgChangeRate":0.022695},{"month":3,"riseRate":0.545455,"avgChangeRate":0.01829},{"month":4,"riseRate":0.181818,"avgChangeRate":-0.111103},{"month":5,"riseRate":0.545455,"avgChangeRate":-0.001774},{"month":6,"riseRate":0.636364,"avgChangeRate":0.009932},{"month":7,"riseRate":0.4,"avgChangeRate":0.063213},{"month":8,"riseRate":0.4,"avgChangeRate":-0.005634},{"month":9,"riseRate":0.2,"avgChangeRate":-0.060144},{"month":10,"riseRate":0.5,"avgChangeRate":-0.035975},{"month":11,"riseRate":0.6,"avgChangeRate":0.058974},{"month":12,"riseRate":0.4,"avgChangeRate":-0.091766}],"exchange":"NASDAQ","name":"Cara Therapeutics","nameEN":"Cara Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.0","shortVersion":"4.24.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cara Therapeutics(CARA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Cara Therapeutics(CARA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Cara Therapeutics,CARA,Cara Therapeutics股票,Cara Therapeutics股票老虎,Cara Therapeutics股票老虎国际,Cara Therapeutics行情,Cara Therapeutics股票行情,Cara Therapeutics股价,Cara Therapeutics股市,Cara Therapeutics股票价格,Cara Therapeutics股票交易,Cara Therapeutics股票购买,Cara Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cara Therapeutics(CARA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Cara Therapeutics(CARA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction